Schellenberg Wittmer advised SIX Swiss Exchange-listed ams-OSRAM AG on the sale of its Passive Optical Components Assets. Focuslight Technologies Inc., a global provider of high-power diode...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised Boerhringer Ingelheim on the deal. Boehringer Ingelheim has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised HOCHDORF Holding AG on the deal. Schellenberg Wittmer advised SIX Swiss Exchange-listed HOCHDORF Holding AG, a Swiss market leader in milk processing, specialising...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised Gilde Healthcare on the deal. Gilde Healthcare’s Private Equity Fund (Gilde Healthcare), a specialized healthcare investor, completed the acquisition of a majority of the...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advises Santhera on license for North America for Vamorolone. Santhera Pharmaceuticals (SIX: SANN) has signed an exclusive license and collaboration agreement for vamorolone in...
You must be a Standard 1 Year member to access this content.
DLA Piper and Schellenberg Wittmer advised Francotyp-Postalia Holding AG on the deal. Bird & Bird, Selmer and Homburger advised Azolver Holding. Francotyp-Postalia Holding AG (FP) executed...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised the shareholders of ASC. All for One Group SE, a leading group in IT/SAP, strategy and management consulting listed in the Prime Standard...
You must be a Standard 1 Year member to access this content.
